VIATRIS INC. Payments for Restructuring
VIATRIS INC. (VTRS) reported Payments for Restructuring of $31.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-08-06
- VIATRIS INC. payments for restructuring for the quarter ending 2026-06-30 was $31.40M.
- VIATRIS INC. payments for restructuring for the quarter ending 2026-03-31 was $5.90M.
- VIATRIS INC. payments for restructuring for the quarter ending 2023-09-30 was $18.40M, a 33.57% decline year-over-year.
- VIATRIS INC. payments for restructuring for the quarter ending 2023-06-30 was $24.10M, a 38.52% decline year-over-year.
- VIATRIS INC. payments for restructuring for fiscal 2021 was $25.70M, a 0.00% change from fiscal 2020.
- VIATRIS INC. payments for restructuring for fiscal 2020 was $25.70M, a 56.73% decline from fiscal 2019.
- VIATRIS INC. payments for restructuring for fiscal 2019 was $59.40M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.40M 10-Q · filed 2026-08-06 | $37.30M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $5.90M 10-Q · filed 2026-08-06 | |||
| 2023-09-30 | $18.40M 10-Q · filed 2023-11-08 | $42.50M derived: sum of 2 quarters · filed 2023-11-08 | $70.10M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2023-06-30 | $24.10M 10-Q · filed 2023-11-08 | $51.70M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2023-03-31 | $27.60M 10-Q · filed 2023-11-08 | |||
| 2022-09-30 | $27.70M 10-Q · filed 2022-11-07 | $66.90M derived: sum of 2 quarters · filed 2022-11-07 | $150.70M derived: sum of 3 quarters · filed 2022-11-07 | |
| 2022-06-30 | $39.20M 10-Q · filed 2022-11-07 | $123.00M derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2022-03-31 | $83.80M 10-Q · filed 2022-11-07 | |||
| 2021-12-31 | $25.70M 10-K · filed 2023-02-27 | |||
| 2021-09-30 | $211.00M 10-Q · filed 2021-11-08 | $287.80M derived: sum of 2 quarters · filed 2021-11-08 | $338.10M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2021-06-30 | $76.80M 10-Q · filed 2021-11-08 | $127.10M derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2021-03-31 | $50.30M 10-Q · filed 2021-11-08 | |||
| 2020-12-31 | $25.70M 10-K · filed 2022-02-28 | |||
| 2019-12-31 | $59.40M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |